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End product (AGE) accumulation to the
decline in motor function
Hans Drenth1,2* , Sytse Zuidema3, Steven Bunt1, Ivan Bautmans4, Cees van der Schans1 and Hans Hobbelen1Abstract
Diminishing motor function is commonly observed in the elderly population and is associated with a wide range
of adverse health consequences. Advanced Glycation End products (AGE’s) may contribute to age-related decline
in the function of cells and tissues in normal ageing. Although the negative effect of AGE’s on the biomechanical
properties of musculoskeletal tissues and the central nervous system have been previously described, the evidence
regarding the effect on motor function is fragmented, and a systematic review on this topic is lacking. Therefore,
a systematic review was conducted from a total of eight studies describing AGE’s related to physical functioning,
physical performance, and musculoskeletal outcome which reveals a positive association between high AGE’s
levels and declined walking abilities, inferior ADL, decreased muscle properties (strength, power and mass) and
increased physical frailty. Elevated AGE’s levels might be an indication to initiate (early) treatment such as dietary
advice, muscle strengthening exercises, and functional training to maintain physical functions. Further longitudinal
observational and controlled trial studies are necessary to investigate a causal relationship, and to what extent, high
AGE’s levels are a contributing risk factor and potential biomarker for a decline in motor function as a component of
the ageing process.
Keywords: Advanced Glycation End products, Motor function, Ageing, Biomarker, Systematic reviewBackground
In the ageing population, decline in motor function such
as reduced walking speed, poor balance, and loss of
muscle strength are commonly observed phenomena
[1–4]. Most human physiologic systems regress with
ageing, independently of substantial disease effects, at an
average linear loss rate of 0.34–1.28 % per year between
the age of 30 and 70 years [5]. The age related loss of
skeletal muscle mass, which is accompanied by muscle
weakness, is an important contributor to functional
decline [6]. More people over the age of 70 are having
difficulties performing everyday functions because of
motor function related problems [7]. Impaired motor
function is a prominent characteristic of physical* Correspondence: j.c.drenth@pl.hanze.nl
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(http://creativecommons.org/publicdomain/zefrailty and is associated with a wide range of adverse
health consequences such as falls, disability, death,
hospitalization, and institutionalization [8, 9]. In addition
to physical frailty, longitudinal studies suggest that a
decreased level of motor function is associated with a
decline of cognitive function and a subsequent devel-
opment of both mild cognitive impairment and Alz-
heimer’s disease [3]. A decline in motor function in
older ages could be predicted by biomarkers which
could allow for early interventions. Since the early
1980’s, it is proposed that the cross-linking of long-
lived proteins mediated by Advanced Glycation End
products (AGE’s) may contribute to the age-related decline
of the functioning of cells and tissues in normal ageing.
AGE’s could, therefore, be a potential biomarker and risk
factor for the decline of motor function in the older popu-
lation [10].is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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The occurrence of AGE’s is mediated by non-enzymatic
condensation of a reducing sugar with an amino group.
AGE’s are spontaneously produced in human tissues as
an element of normal metabolism which increases with
aging [11–14]. The increase of the level of free/unbound
and protein bound AGE’s in the blood circulation is also
determined by an exogenous intake such as food [15].
AGE’s are being removed from the body through enzym-
atic clearance and renal excretion.
It has been proposed that, with ageing, there is an imbal-
ance between the formation and natural clearance of AGE’s,
leading to the accumulation of AGE’s in tissues [16, 17]. In
many age related diseases, the accumulation of AGE’s is a
significant contributing factor in degenerative processes, es-
pecially in renal failure, blindness, cardiovascular diseases,
and complications of diabetes mellitus [13, 18]. Elevated
AGE’s levels in patients with diabetes mellitus (DM) is most
likely due to an excessive elevation of glucose concentration
which consequently accelerates the glycation of proteins
[11, 13, 18]. Furthermore, AGE’s play a role in neurological
disorders such as Alzheimer’s Disease (AD) [13, 19]. Inter-
estingly, Hobbelen et al. [20] ascertained that patients in
early stage of dementia and with DM had a significantly
higher risk for the development of muscle stiffness/hyper-
tonia (defined as paratonia) compared to those with de-
mentia but without DM (OR= 10.7, 95 % CI:2.2–51.7). In
early stage dementia, paratonia already negatively and sig-
nificantly impacts functional mobility such as walking
speed. As the most common cause of dementia, Alzhei-
mer’s disease, as well as DM, are related to higher serum
concentrations of AGE’s, the previous finding in the Hob-
belen et al. study prompted the hypothesis that AGE’s may
partly or indirect be responsible for the development of
paratonia. The pathogenesis of paratonia is unclear and
central nervous system changes as well as peripheral bio-
mechanical changes are hypothesized [20].
Several types of AGE’s have been described and can be
categorised into fluorescent cross-linking AGE’s, non-
fluorescent cross-linking AGE’s, and non-crosslinking
AGE’s. The best chemically characterized AGE’s are Pento-
sidine (fluorescent cross-linking) and Carboximethyl-lysine
(CML, non-cross-linking) [21]. Cross-linking AGE’s are re-
sponsible for an increasing proportion of insoluble extracel-
lular matrix and thickening of tissue as well as increasing
mechanical stiffness and loss of elasticity [12, 22, 23].
Cross-linking AGE’s are considered as being involved in the
pathophysiology of arthritis [24, 25]. In fact, the accumula-
tion of AGE’s in human articular cartilage increases cartil-
age stiffness and brittleness. Consequently, the cartilage
becomes increasingly prone to damage and degeneration
[26, 27]. In rheumatoid arthritis, elevated levels of cross-
linking AGE’s in serum and/or synovial fluids also appear
to correlate with the levels of inflammatory markers andthe disease activity [24]. Another impact on the
musculoskeletal system is within the skeletal bone
where AGE-induced crosslinks in the collagen matrix
alter the mechanical properties of bone by increasing
stiffness and fragility [27–29]. Furthermore, signifi-
cantly higher AGE’s levels were reported in patients
with osteoporosis, thereby increasing the risk of
fractures [28, 30].
Non cross-linking effects are exerted by the binding of
AGE’s to the receptor for AGE’s (RAGE). A wide variety
of cells express RAGE, and the interaction with AGE’s
incites activation of intracellular signalling, gene expres-
sion, and production of pro-inflammatory cytokines
(such as Interleukin (IL)-6, Tumor Necrosis factor
(TNF)-alpha), and free radicals. At the peripheral (tissue)
level, these inflammatory processes exhibit powerful pro-
teolytic activity whereby the collagen becomes more vul-
nerable and tissue elasticity decreases [31, 32]. At the
central level (central nervous system), interaction be-
tween AGE’s, Amyloid-beta and hyperphosphorylated
tau-protein induce microglia and astrocytes to upregu-
late the production of reactive oxygen species, pro-
inflammatory cytokines, and nitric oxide which affects
neuronal function [11, 32].
Numerous reviews [16, 33–39] on the relation be-
tween AGE’s and motor function have been published,
but the majority of these studies are narrative reviews
and therefore showing most often an indirect relation-
ship. The negative effect of accumulating AGE’s on the
biomechanical properties of peripheral musculoskeletal
tissues and the central nervous system (CNS), for ex-
ample accumulation in specific relevant motor-related
brain regions, will plausibly have an impact on motor
function. However, evidence regarding this subject is
fragmented, and a systematic review on this topic is
lacking. Therefore, the aim of this study was to system-
atically review the literature for the direct relationship
between circulating and/or tissue AGE’s and motor
function.Methods
Search strategy
The Embase, Pubmed, Cinahl, and Web of science da-
tabases were searched from the earliest possible date
through January 2016. Terms were employed both as
free text words and mapped to subject headings terms
with explosion when feasible. We utilized all possible
relevant terminology regarding AGE’s and motor func-
tion (decline). For detailed information on search
terms, see Table 1. The search regarding terms for
AGE’s were combined with our search (with AND)
regarding terms for motor function (decline). Search
filters were established for studies on humans and the
Table 1 Detailed search terms
Entry Keywords
AGE’s “advanced glycosylation end products” (OR) “advanced glycosylation end products receptor (supplementary concept)” (OR)
“advanced glycation end product(s)” (OR) “advanced glycation end product(s) receptor” (OR) “non-enzymatic glycation” (OR)“
non-enzymatic glycosylation” (OR) “glycotoxins”.
AND
Motor function “musculoskeletal physiological phenomena” (OR) ”muscle fatigue” (OR) “muscle strength” (OR) “muscle rigidity” (OR) “muscle tonus”
(OR) “muscle stiffness” (OR) “mechanical stiffness” (OR) “rigidity” (OR) “ physical endurance” (OR) “postural balance” (OR) “balance”
(OR) “posture” (OR) “postural control” (OR) “articular range of motion” (OR) “psychomotor performance” (OR) “motor activity” (OR)
“motor skills” (OR) “motor skills disorders” (OR) “coordination” (OR) “motor coordination” (OR) “motor control” (OR) “eye-hand
coordination” (OR) “fine motor” (OR) “fine motor skills” (OR) “neuromuscular manifestations” (OR) “gait” (OR)“gait disorders” (OR)
“walking” (OR) “locomotion” (OR) “falls (accidental)” (OR) “mobility limitation” (OR) “physical mobility” (OR) “physical performance” (OR)
“physical activity” (OR) “activities of daily living” (OR) ”motor function” (OR) “motor function decline” (OR) “mobility impairment” (OR)
“functional decline” (OR) “motor inhibition” (OR) “inhibition of action” (OR) “interlimb” (OR) “interlimb coordination”.
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from identified articles were reviewed for additional
references.
Inclusion criteria and outcome variables
Studies were included providing that a direct relation-
ship between measured AGE’s levels and motor func-
tion was described. Motor function was defined as
any movement or activity through the use of motor
neurons in a broad sense (i.e. motor skills, motor
control, coordination, locomotion etc.) and/or physical
performance (i.e., activities of daily life (ADL), walk-
ing, stair climbing, etc.) and/or musculoskeletal func-
tion (i.e., muscle strength or stiffness, range of
motion etc.). Studies were excluded when merely the
effects of AGE’s on tissue level or their relation with
specific diseases where described, without any direct
outcome on motor function.
Data extraction and study quality
Data were independently extracted by two reviewers. A
standardized data extraction form was exploited to de-
rive the following data from each eligible study: first au-
thor, year of publication, study design, study population
(age, gender, and co-morbidity); the type of AGE’s (e.g.,
crosslinking, non-crosslinking, and chemical characteris-
tics); and the outcome of motor function and the
strength of the relationship between AGE’s and motor
function (e.g., correlation coefficients, risk ratio’s etc.).
The methodological quality of each incorporated study
was assessed independently by two reviewers. All eligible
studies turned out to be observational studies and were
assessed with the 12 item EBRO Assessment Tool of Co-
hort Studies [40]. This tool comprises eight validity
questions, one question to decide whether to continue
the checklist, two applicability items, and one item for
statistical analysis. The two applicability items were dis-
regarded as they merely answer questions to determine
if the results are applicable to Dutch healthcare. There-
fore, ten criteria remained (Table 2). The includedstudies were qualified as “good”, “moderate”, or “low”.
To qualify as “good”, the study should rate “valid and
applicable” and include sufficient statistical analyses
(e.g., correction for potential confounders). A “moder-
ate” qualification was assigned when the validity items
rated “doubtful” and included sufficient statistical ana-
lyses or rated only “valid and applicable” for the validity
items. Any other scenario would have given the study a
“low” methodological qualification (Table 2). In the
event of a discrepancy, the final score was decided by
consensus.Statistics
Risk ratios (RR), Odds ratio’s (OR), Hazard ratio’s (HR),
correlation coefficients, and group differences (mean
difference and 95 % confidence interval) were presented
as reported in the studies. The subjects’ ages were pre-
sented as reported in the studies or in means and stand-
ard deviations (SD) that were calculated from the
available data. If association coefficients were not avail-
able, effects sizes (ES) [41] were calculated to estimate
the magnitude of the effect of AGE’s on specific out-
comes when the mean difference and standard deviation
of compared groups were available or could be retrieved
from confidence intervals.
The following formula were used:
SD ¼ √ number of subjectsð Þ
 upper limit − lower limit½ = 2  1:96ð Þ
ES ¼ mean 1 – mean 2½ =SD pooled; where SD pooled




Cohen’s benchmarks were used to indicate small
(ES = 0.20), medium (ES = 0.50), and large (ES = 0.80)
effects size [42]. Due to the heterogeneity across the
studies, meta-analysis was not performed.
Table 2 Methodological quality of observation studies with EBRO assessment tool of cohort studies [38]
















1. Are the comparing groups clearly
described?
Yes Yes Yes Yes Yes Yes Yes Yes
2. Can risk of bias sufficiently be
excluded?
Yes Yes Yes Yes Yes Yes Yes No
3. Is the exposure clearly described
and is the method for assessing
the exposure adequate?
Yes Yes Yes Yes Yes Yes Yes Yes
4. Is outcome clearly described and
is the method for assessing the
outcome adequate?
Yes Yes Yes Yes Yes Yes Yes Yes
5. Has exposure outcome been
blinded?
Yes Yes Yes Yes Yes Yes Yes Yes


























8. Have important confounders or
prognostic factors been identified
and are they taken into account
in the design or analysis?
Yes Yes Yes No Yes No Yes Yes
9. Are the study results valid and
applicable?
Yes Yes Yes Yes Yes Yes Yes Yes
10. Correction for potential
confounders: Odds ratio (OR),
Relative Risk (RR), Absolute Risk
Reduction (ARR), Mean Difference
(MD), Hazard Ratio (HR)
Yes Yes Yes No Yes No Yes Yes
Overall quality score Good Good Good Moderate Good Moderate Good Good
To be eligible for further statistical analysis, the study results should rate “valid and applicable” or “doubtful” on question 9. To qualify “valid and applicable” a
longitudinal study had to score “Yes” on the 2 follow up questions (6 and 7) and more than 4 times a “yes” on the remaining validity items (1 t/m5 and 8). A
“doubtful” qualification was given when 4 times a “yes” was scored on the remaining validity items (1 t/m5 and 8). When a study scored “yes” less than 4 times
on the remaining items, further analysis with the checklist was cancelled. When the study had a cross-sectional design the two questions regarding follow up
(6 and 7) were disregarded
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Search results
The literature search revealed 1154 hits. After eliminat-
ing 208 duplicates and after an initial screening of titles
and abstracts, 902 studies were excluded. Primary reason
for exclusion were that the studies were describing an
(indirect) effect only on tissue level (n = 223), were dis-
ease related (n = 291) or in the field of diet and weight
(n = 16), all without outcome on movement, activity,
performance and or function. The remaining excluded
studies (n = 372) did not meet the inclusion criteria in
general. A total of 44 full-text articles were retrieved for
further analyses. Examination of the available reference
lists of these 44 studies did not reveal additional studies.
From the 44 potentially eligible studies, 36 studies were
excluded because no relevant outcomes were described
(n = 19), were narrative reviews (n = 11) or were confer-
ence abstracts (n = 4) and editorial comments (n = 2).
Finally, eight studies were included for this review. A
flowchart of the selection process is presented in Fig. 1.Study quality
The study quality of six studies was scored as “good”
[43–48]. A moderate score was assigned to two studies
[49, 50] because potential confounders were not taken
into account in the analysis (Table 2).
Data extraction
Study design
Of the eight included studies, six had a cross-sectional
design [43–45, 48–50], one had a longitudinal design
[46], and one study employed a mixed longitudinal and
cross-sectional design [47].
AGE’s type
The chemical characteristics of the reported AGE’s was de-
scribed in six studies [43, 45–49]. Carboxymethyl-Lysine
(CML) was quantified in five studies [43, 45–47, 49] and
Pentosidine in one study [48]. In two studies the chemical
characterisation of the AGE’s were not specified, yet mea-
sured indirectly by skin fluorescence [44, 50]. For obtaining
Duplicates 
n= 208 
946 studies screened on title and 
abstract           
1154 studies identified through 
database searching
Embase  n= 639 
Pubmed  n= 262 
Web of science n=  223 
Cinahl   n=    30 
Excluded 
Not meeting inclusion criteria n= 902 
- tissue level n=223  
- diseases n= 291  
- weight and diet n= 16 
- other n= 372
946 studies after removing 
duplicates    
44 potential studies screened full 
text            
Excluded 
Not meeting inclusion criteria n=36 
- conference abstract n=4 
- editorial comment n=2 
- narrative review  n=11 
- no relevant or outcomes n=19 
 8 studies included for review 
Fig. 1 Flow Chart of selection process
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[43, 45–48]; tissue samples in one study [49]; and the non-
invasive AGE reader in two studies [44, 50].
Motor function outcomes
The outcomes for motor function from the eight re-
trieved studies were categorized into three categories;
1) Physical performance and functioning: walking
abilities [45, 46], activities of daily living (ADL)
[47] and upper extremity function [50];
2) Musculoskeletal: muscle strength, power and
mass [43, 44, 48, 49];
3) Physical frailty: in accordance with the Fried criteria
[8] and defined as having three or more of the
following characteristics: low physical activity,
exhaustion, slow walking speed, decreased muscle
strength, and unintentional weight loss [47].Study characteristics and an overview of the main
findings and statistics from the studies are provided in
Table 3.
Relationship of AGE’s with physical performance and
functioning
Walking abilities
Walking and the relationship with Carboxymethyl-
Lysine (CML) was studied in two studies [45, 46]. In the
cross-sectional study by Semba et al. [45], walking speed
was assessed in a representative sample of community
dwelling elderly (n = 944). Slow walking speed was
defined as the slowest quintile of walking speed which
was <0.79 m/s. Plasma CML was divided into quartiles
with the cut-off at the highest quartile established at
424 ng/mL. The study demonstrated that, after adjusting
for covariates (age, education, smoking, cognition status,
depression, and chronic disease), the subjects in the
Table 3 Study characteristics
First author/year
of publication
Design Population n =, age,
gender and co-morbidity
AGE/RAGE Circulating/












older adults N = 944
(416 M, 528 F), aged
75 ± 7 years
Circulating plasma
CML (cut-off value for





Risk for slow walking speed with
high AGE’s level:
OR = 1.60 (95 % CI:1.02–2.52)*c
OR = 1.87 (95 % CI:1.15–3.04)*c








dwelling F, N = 394, aged
76 ± 8 years
Circulating serum
CML (cut-off value for






Walking disability risk with high
AGE’s level:
HR = 1.68 (95 % CI: 1.11–2.52)*
HR = 1.63 (95 % CI: 1.06–2.49)*c(1)
HR = 1.56 (95 % CI: 1.04–2.36)*c(2)
HR = 1.54 (95 % CI: 1.04–2.29)*c(3)










older adults N = 3373
(1344 M, 2029 F) aged
78.1 ± 4.8 years
Circulating serum
CML (cut-off value for
high level = 620 ng/mL)
ADL disability
Physical frailty ≥3 of following
characteristics:
1. Low handgrip strength
2. Unintentional weight loss
3. Low physical activity
4. Exhaustion
5. Slow walking speed
ADL disability risk with high
AGE’s level:
HR = 1.08 (95 % CI: 1.03–1.13)*b
HR = 1.10 (95 % CI: 1.05–1.15)*c
HR = 1.05 (95 % CI: 1.01–1.11)*c
(+ adjusted for arthritis, cognition,
kidney disease)
Physical frailty risk with high AGE’s
level in men:
HR = 1.30 (95 % CI: 1.14–1.48)*b
HR = 1.24 (95 % CI: 1.07–1.45)*c
HR = 1.10 (95 % CI: 0.92–1.32) NS.c
(+ adjusted for arthritis, cognition,
kidney disease)
Physical frailty risk with high AGE’s
level in women:
HR = 1.06 (95 % CI: 0.91–1.23) NS.b
HR = 1.06 (95 % CI: 0.90–1.24) NS.c
HR = 0.91 (95 % CI: 0.77–1.07) NS.c




Cross-sectional DM2 patients N = 26
(13 M, 13 F) aged
64,5 ± 6,8 Non DM N = 26












Correlation flexor strength and
AGE’s level: R = 0,07 NS
Correlation Upper extremity
disability and AGE’s level:
R = 0,51*
Correlation Upper extremity





















Table 3 Study characteristics (Continued)
Dalal et al.
2009 [43]
Cross- sectional Moderately to severe
disabled community
dwelling F, N = 559,
aged 76 ± 8 years
Circulating serum
CML (cut-off value for
high level = 0.68 mg/mL)
Handgrip strength - Group difference high vs. low
AGE’s level:
18.2 (6.4) kg. vs. 20.1 (6.2) kg.,
Beta −1.88 (SE = 0.65)* 18.6 kg
vs. 20.0 kg, Beta −1.31
(SE = 0.61)*c
De La Maza
et al. 2008 [49]
Cross-sectional Healthy M, N = 21−
Weight maintainers,
N = 10,− aged 41 ±
4 years− Weight gainers,
N = 7, aged 42 ± 5 years
− Elderly, N = 4, aged
67 ± 2 years
Skeletal muscle tissue
CML/RAGE
Handgrip strength - Correlation grip strength and
AGE’s level: R = −0,54*
Momma et al.
2011 [44]
Cross-sectional Healthy M, aged 46 years
(37–56)a- Grip strength






AGE’s) (cut-off value for





- Group difference high vs low
AGE’s level:
1. Muscle (handgrip)strength:
41.7 (95 % CI: 40.3- 43.1) kg.
vs.44.5 (95 % CI: 43.2- 45.9) kg.*c
ES = 0.45
2. Muscle (leg extension) power:
16.0 (95 % CI: 14.9- 17.1) W/kg.
vs.17.8 (95 % CI: 16.6- 19.1)
W/kg.*c ES = 0.44
Tanaka et al.
2015 [48]
Cross-sectional DM2 patients, F, N = 133,










Association UMM and AGE’s
level: R = −0.11 NS Beta −0.11 NS
Association LMM and AGE’s
level: R = −0.21* Beta −0.18*
Association RSMI and AGE’s
level: R = −0.18* Beta −0.27*
M Male, F Female, yrs years, AGE Advanced Glycation End product, RAGE Receptor for Advanced Glycation End products, CML Carboxy-methyl-Lysine, DM2 Diabetes Mellitus type 2
aMedian (interquartile range), ES Effect Size, OR Odds Ratio, HR Hazard Risk
bmultivariate adjusted for demographics
cidem +multivariate adjusted for potential confounders. NS Not significant. (1) All women with missing data had multiple simulations to impute walking disability status prior to death. (2) Inverse probability weighting
method. (3) All women with missing data treated as developing walking disability prior to death. (4) All women with missing data treated as censored, that is, no walking disability prior to death, UMM Upper extremity
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of a slow walking speed (OR = 1.60, 95 % CI: 1.02–
2.52, P = 0.04) compared to those in the lower three
quartiles of plasma CML. After an exclusion of subjects
with diabetes and adjusting for the same covariates, the
study showed that participants in the highest quartile of
plasma CML were at a higher risk for slow walking speed,
(OR = 1.87, 95 % CI 1.15–3.04, P = 0.01). In the longitu-
dinal study by Sun et al. [46], walking speed and serum
CML were measured in moderately to severely disabled
community dwelling female subjects (n = 394). Walking
disability was defined as the inability to walk or a walking
speed of <0.4 m/s. Cut-off values according to plasma
CML quartiles were 452.6, 558.8 and 689.1 ng/mL. The
study showed that subjects in the highest quartile of
CML were at a greater risk for developing a walking
disability (HR = 1.68, 95 % CI: 1.11–2.52, P = 0.03).
Multivariable hazard models for different missing data
scenario’s (for details, see Table 3) and adjusting for
health characteristics (age, congestive heart failure,
peripheral artery disease, diabetes mellitus type 2
(DM2), and renal insufficiency) revealed a significantly
higher risk for women in the highest quartile of CML
to develop a walking disability (HR’s between 1.46
and 1.63, all p < 0.05).Activities of Daily Living (ADL)
The ability to perform ADL activities and the longitu-
dinal relation with CML in older persons was described
in the study by Whitson et al. [47]. Serum CML was
measured in participants in the Cardiovascular Health
study (n = 3373) and was divided into quintiles with the
cut-off for the two highest quintiles established at
620 ng/mL. ADL disability was defined as difficulty (yes
or no) in any of six ADL activities such as walking
around the home, getting out of bed/chair, dressing,
bathing, eating, and toileting and was assessed at 6- or
12- month intervals for 14 years. AGE levels were com-
pared between the groups with and without difficulty on
the specific ADL activities. After adjusting for potential
confounders (demographics, BMI, DM2, alcohol con-
sumption, smoking status, total cholesterol, albumin,
weight change, hypertension, heart disease, stroke, and
claudication), a high level CML at baseline was associ-
ated with 10 % (95 % CI 5 %–15 %) higher incidence of
a first ADL difficulty with a hazard ratio (HR) of 1.10
(95 % CI:1.05, 1.15), p < 0,01) per standard deviation
(225 ng/mL CML). After further adjusting for arthritis,
cognition, and kidney function, an increase in CML
was associated with a 5 % (95 % CI 1 %–10 %) higher
incidence of disability, HR of 1.05 (95 % CI:1.01–1.11,
P = 0.03) per standard deviation (225 ng/mL CML) in
both males and females.Upper extremity function
Upper extremity function and the relation with AGE’s
was studied by Shah et al. [50] in groups with
diabetes mellitus type 2 (DM2) (n = 26) and without
DM2 (n = 26). Upper extremity disability was mea-
sured using the Disability of the Arm, Shoulder and
Hand (DASH) self-report questionnaire. The DASH
has 30 questions, including disability and pain. The
scores were calculated for a range between 0 and
100 %, where a higher number indicates more impair-
ments. Skin tissue fluorescent AGE’s levels were
assessed utilizing an AGE reader. The AGE reader
auto-fluorescence (AF) was correlated to the DASH
scores (r = 0.51, P = 0,009) indicating that higher AGE
levels correlate with increased disability of arm, shoulder
or hand. They also studied the three-dimensional humer-
othoracic and glenohumeral joint motion and found that
AGE reader levels were negatively correlated to
humerothoracic elevation (r = −0.44, P = 0.024), but not
correlated to glenohumeral external rotation (r = −0.32,
P = 0.13).
Relationship of AGE’s with Musculoskeletal outcome
Muscle strength and power
The contribution of AGE’s on the muscle properties
strength and power was described in four studies
[43, 44, 49, 50]. Dalal et al. [43] examined handgrip
strength and circulating CML concentrations in mod-
erately to severely disabled, older females (n = 559).
The quartile cut-offs for serum CML were 0.45, 0.55, and
0.68 mg/mL. Women in the highest quartile of CML ex-
perienced decreased mean grip strength compared with
women in the lower three quartiles, 18.6 kg. vs. 20.0 kg,
respectively, with a Beta of −1.88 (SE = 0.65, P = 0.004).
After adjusting for covariates (age, race, BMI, cognition,
depression, and DM2), a difference was reported of 18.2
(6.4) kg. vs. 20.1 (6.2) kg, respectively, with a Beta of −1.31
(SE = 0.61, P = 0.03). The evidence of tissue CML/RAGE
in skeletal muscle (internal abdominal oblique) biopsies of
healthy subjects (n = 21) differing in age and weight stabil-
ity was studied in the cross-sectional study by de la Maza
et al. [49]. The subjects (n = 21) were divided into a group
of self-reported weight maintainers (WM)(n = 10);
self-reported weight gainers (WG) (n = 7); and elderly
(E) (n = 4). The study ascertained that handgrip
strength was diminished in subjects with an increase
of CML/RAGE in muscle tissue and reported a nega-
tive correlation (r = −0.54, p < 0.05) between tissue
CML and handgrip strength.
The relationship between AGE’s and grip strength and
leg extension power was described in the study by
Momma et al. [44]. In their study, healthy adult males
(n = 370) were divided into two groups, i.e., one group
(n = 232) for analysing grip strength and another group
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cent AGE’s levels were assessed utilizing an AGE reader.
The tertile cut-off ranges for the AGE reader auto-
fluorescence (AF) were 1.28–1.84, 1.84–2.09 and 2.09–
4.44. After adjusting for potential confounders (age,
BMI, physical activity, smoking/drinking status, depres-
sion, education, occupation, total energy consumption,
metabolic syndrome, DM2, kidney disease, and dietary
intake of vitamin C), it was discovered that grip strength
was 6.3 % less for those in the highest tertile than for
subjects in the lowest tertile of skin AF (P = 0.01). Leg
extension power was 10 % lower for those in the highest
tertile than for the lowest tertile of AF (P = 0.04).
Shoulder flexor muscle strength and the relation with
AGE’s was described in the study by Shah et al. [50] in
groups with DM2 (n = 26) and without DM2 (n = 26).
Skin tissue fluorescent AGE’s were assessed utilizing an
AGE reader. The study revealed that AGE reader auto-
fluorescence (AF) was not related to shoulder flexor
muscle strength (r = 0.07, P = 0.7).
Muscle mass
Loss of muscle mass and the relation with serum levels
of Pentosidine was studied in the study by Tanaka et al.
[48] In this study among postmenopausal women with
DM2 (n = 133) upper and lower extremity muscle mass
was measured by Dual-energy x-ray absorptiometry and
also the relative skeletal muscle mass index (RSMI = ap-
pendicular skeletal muscle mass/height2) was calculated.
They showed that serum Pentosidine levels were
negatively correlated with muscle mass of the lower
extremity (r = −0.21, P = 0.0017) and RSMI (r = −0.18,
P = 0.039), but not with the muscle mass of the upper
extremity (r = −0.11, P = 0.219). After correction for
covariates (age, DM2 duration, serum creatinine, gly-
cosylated haemoglobin (HbA1c) and insulin-like
growth factor-1 (IGF-1)) they reported that serum
Pentosidine levels were associated with RSMI with a
Beta of −0.27 (P = 0.008) and muscle mass of the
lower extremity with a Beta of −0.18 (P = 0.071).
Relationship of AGE’s with physical frailty
Physical frailty in relation to CML was reported by
Whitson et al. [47]. Frailty was based on the five criteria
previously described by Fried el al. [8]: less physical ac-
tivity, self-reported exhaustion, decreased grip strength,
slow walking speed, and unintentional weight loss.
Participants with three or more criteria were classified as
physically frail. In this cross-sectional study serum, CML
was measured in older, healthy participants (n = 3373).
Self-reported exhaustion was identified by evaluation of
two statements of the Centre for Epidemiological Studies
Depression Scale (CES-D) and was regarded positive if at
least one condition was evident for three or more daysduring the previous week. The decreased physical
activity criterion was positive if physical activity per
week was <383 kcal/week for men and <270 kcal/
week for women. Slow walking speed and inadequate
grip strength were defined as the lowest 20 % of the
population. Finally, unintentional weight loss was de-
fined as unintentional loss of 4.5 kg in the year prior
to the current evaluation or unintentional weight loss
of at least 5 % of the previous year’s body weight.(7)
AGE levels were compared between groups with or
without presence of the specific frailty components.
Mean CML levels were significantly higher in men for
low physical activity (p = 0.007), exhaustion (p < 0.001)
and decreased grip strength (p = 0.04), resulting in a
significant association with the physical frailty pheno-
type (OR = 1.30, 95 % CI:1.14–1.48, p < 0.001). After
adjusting for potential confounders (demographics,
BMI, DM2, alcohol consumption, smoking status,
total cholesterol, albumin, weight change, hypertension,
heart disease, stroke, and claudication), a significant asso-
ciation remained (OR = 1.24, 95 % CI:1.07–1.45, p = 0,04).
The associations lost significance after further adjustment
for arthritis, cognition, and kidney function. No significant
associations between CML and low physical activity,
exhaustion, and grip strength were determined for
females. Furthermore, in men and women with a slow
walking speed and unintentional weight loss, CML levels
were higher, however, these differences in CML levels
were not significant.
Discussion
The results of this systematic review indicate that higher
levels of AGE’s are independently related to declined
walking abilities, inferior ADL, decreased muscle proper-
ties (strength, power, mass) and increased physical
frailty.
The available literature on musculoskeletal outcomes
[43, 44, 48, 49] support the hypothesis that high AGE’s
levels are associated with a decline in muscle function.
However, the correlations, Beta coefficients and calcu-
lated effect sizes indicate only a moderate relationship. It
is known that AGE’s can affect muscle function through
a variety of pathways. In fact, AGE’s can alter the
biomechanical properties of muscle tissue, increasing
stiffness and reducing elasticity through cross-linking
and upregulated inflammation by RAGE binding and
endothelial dysfunction in the intra-muscular microcir-
culation [43–46, 49, 51]. This is also consistent with
studies on sarcopenia in which decreased muscle mass
and strength is explained by an overall increase in
inflammatory burden [6]. Examining the studies in this
review that report decline in walking abilities, it is sug-
gested by the authors that this decline is also attributed
to the effects of AGE’s on muscle tissue, thereby
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ered that impaired muscle function - through AGE’s-in-
duced muscle damage – can contribute to decline in
walking abilities and ADL and can also contribute to
physical frailty.
It remains ambiguous to what extend ADL involving
the upper extremity are affected by high AGE’s level.
One small study [50] reports a relation with upper ex-
tremity disability, but further we could not identify
which ADL are affected most by AGE’s and if at all are
related to upper extremity function. Thereby in a large
study [47] the reported increased risk in inferior ADL is
described as the association between baseline AGE’s
level and the time to first difficulty on any of the six
self-reported ADL items and, although significant, the
risk is low (HR = 1.10), therefore the practical import-
ance is unclear.
Furthermore our review shows that the decline of
handgrip strength is positively associated with higher
AGE levels in three studies [43, 44, 49]. Interestingly, in
the upper extremity shoulder muscles no association
with high AGE levels is found in two studies [48, 50].
The underlying mechanism for this difference in the
upper extremity remains unclear and further research is
necessary on this topic.
We identified only 8 studies due to strict inclusion
criteria for several reasons; 1) We restricted the inclu-
sion to individual studies that reports a direct rela-
tionship between AGE’s and functioning which
enabled us to calculate effect sizes, association coeffi-
cients etc. for direct comparison of the strength of
the association. 2) To increase internal validity we
were specifically interested in motor functioning so
we excluded papers measuring solely an effect on
tissue levels. 3) Also we did not include papers that
only cover a specific disease (such as Diabetes) to
increase external validity. As mentioned previously, AGE’s
have an effect on different types of human tissues [24, 26,
31, 32]. It must be considered that other AGE’s-induced
effects, such as effects on the nervous system, ligaments,
tendons or joint capsules, could contribute to the decline
of physical performance and functions. Future research
should, therefore, explore other possible underlying AGE’s
related pathways, not only on the pathophysiological
changes on the tissue level, but also with a direct relation
on motor function.
The current systematic review shows that the relation
between AGE’s and motor function is not as strong as
most narrative reviews suggest. Although the quality of
the included studies was good to moderate, they
employed a cross-sectional or observational design,
therefore, a causal relationship cannot be inferred. A
meta-analysis was not appropriate because of the hetero-
geneity of the studies.It is known that, in addition to cognitive decline,
accompanying decline in motor function is frequently
reported in patients with dementia [52] and it is
suggested that AGE’s formation may explain many bio-
chemical and neuropathological changes in the most
common cause of dementia [13]. However, the results
from this review provide no conclusive evidence for a
peripheral or a central level effect of AGE’s on motor
function in Alzheimer’s disease or other types of demen-
tia. We were unable to locate any study describing the
effect of AGE’s on the CNS with a direct relation on
motor function. It remains unclear if AGE’s accumulate
in specific relevant motor-related brain regions, having
their effect on the complex inter-relationship between
the distributed motor networks within the CNS as well
as with the musculoskeletal structures for generating
movement. Future research is required to determine the
contribution of AGE’s accumulation on the CNS with a
direct relation on the decline in motor function.
It is important to realise that, in this review, decline in
motor function was primarily associated with elevated
CML levels. Association with circulating CML was
determined in four studies [43, 45–47], and a relation
with tissue CML was found in one study [49]. One study
reported an association with Pentosidine [48] and two
other studies with non-specified skin tissue fluorescent
AGE’s [44, 50]. It is suggested that fluorescent and non-
fluorescent AGE’s such as CML behave similarly and
fluorescence may be employed as a marker for the total
skin tissue AGE’s pool [53]. Although CML is a domin-
ant AGE in blood circulation and correlates with other
AGE’s [14], it is possible that the association between
AGE’s and motor function outcome could be different if
crosslinking AGE’s such as Pentosidine were assessed.
In five studies, only females [43, 46, 48] or males
[44, 49] were included, therefore, the reported decline
in motor function with elevated AGE’s cannot neces-
sarily be extrapolated to the other gender. Previous
longitudinal studies conducted in a large cohort suggest
that the relation between serum AGE’s and health elevated
levels of serum AGE’s were associated with all-cause
mortality, cardiovascular disease, and coronary heart dis-
ease mortality only in women [54, 55]. In contradiction,
Whitson et al. [47] found a significant cross-sectional as-
sociation between CML and physical activity, exhaustion,
and muscle strength as components of physical frailty only
among men and not among women. A possible explan-
ation suggested by Whitson et al. is that aged cohorts may
be subject to gender-specific survivor bias. They state that
the relative significance of CML mediated factors in deter-
mining the risk of death is greatest for females prior to
menopause but greater for men in advanced ages. If AGE’s
have more effect on women, higher-risk women may then
be unlikely to participate in studies that measure CML late
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other hand, they did find an association with men and
women in their longitudinal study on ADL disability. In a
comparable cohort, Semba et al. [45] reported a strong
association between men and women and do not report
any significant gender differences. Therefore, this raises an
additional question of whether or not the effect of
AGE’s could be gender specific. Future research
should, therefore, include gender-based differences in
the effects of AGE’s.
The vast majority of participants included in this re-
view were elderly people older than 64 years (n = 5433).
Interestingly, in two studies [44, 49], the participants
were middle-aged between 37 and 56 years (n = 387).
This indicates that the negative effect of AGE’s on motor
function already begins during midlife and, as AGE’s
levels increase with ageing, could be an important factor
in age related decline in motor function. A high AGE’s
level, as a biomarker, therefore, could predict a decline
in motor function later in life. This could also imply that
preventive interventions should start as soon as possible
as part of healthy ageing. In accordance with the results
of this review, it would be interesting to investigate
whether motor function can be improved by reducing
AGE’s levels. Intensive glycaemic control may be a
method to decrease AGE’s formation. CML levels correl-
ate to dietary consumption [14], therefore, dietary intake
is a possible factor that can be influenced. It is suggested
that, in order to lower daily AGE’s intake, foods rich in
sugar and fat and those prepared by frying or grilling
should be avoided [14, 56]. However, evidence of the
harmful effects of long-term exposure to dietary AGE’s
is still inconclusive [15]. Improvements of glycaemic
control by regular physical exercise could also attenuate
the formation and accumulation of AGE’s [11, 21, 57].
Elevated AGE’s levels might be an indication to initiate
(early) treatment such as dietary advice, muscle
strengthening exercises, and functional training to main-
tain physical functions. However, literature regarding the
effects of physical exercise on AGE’s formation is
minimal, and the optimal exercise modalities remain
ambiguous [21]. Further research should focus on
whether dietary modifications, exercise programs, or
medication to reduce AGE’s levels can prevent or coun-
ter decline in motor function.
Conclusion
This review indicates that decline in motor function is
independently associated with high AGE’s levels. Further
longitudinal observational and controlled trial studies
are necessary to investigate a causal relationship, and to
what extent, high AGE’s levels are a contributing risk
factor and potential biomarker for decline in motor
function as a component of the ageing process.Abbreviations
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